Key facts
- BreakBio’s last known valuation is $29.4M (Apr 2025).
- It has raised $2.0M; the latest was Seed Round ($2.0M) in Apr 2025.
- Notable investors include Endless Frontier Labs, GreatThings.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for BreakBio
- ·The full record, as it builds
Funding rounds
No funding rounds for BreakBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BreakBio
Operator of a biopharmaceutical platform intended to deliver personalized cancer immunotherapy for precise and targeted treatment. The company offers AI-driven, patient-specific peptide vaccines and medications that stimulate T-cell responses against non-mutated cancer targets, enabling individuals with solid tumors to receive tailored therapies that the immune system would not naturally initiate.
- Sector
- Healthcare
- HQ
- Miami, FL, United States
- Founded
- 2019
- Employees
- 9
- Website
- breakbio.com/
- Ownership
- Privately Held (backing)
BreakBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BreakBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BreakBio in its N-PORT filings yet. We sweep new filings monthly.